A phase II, multicenter, open-label, dose-finding study evaluating THIO sequenced with cemiplimab in patients with advanced NSCLC

被引：0
|
作者：
Ciuleanu, T-E. [1 ]
Joshi, R. [2 ]
Gryaznov, S. [3 ]
Vitoc, V. [3 ]
Obrocea, M. [3 ]
机构：
[1] IOCN Oncol Inst Prof Dr Ion Chiricuta, Med Oncol, Cluj Napoca, Romania
[2] Canc Res SA, Med Oncol, Adelaide, SA, Australia
[3] MAIA Biotechnol Inc, Clin Dev, Chicago, IL USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1316
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1193TiP
引用
收藏
页码：S1094 / S1094
页数：1
相关论文
共 50 条
  • [1] A phase 2, multi-center, open-label, dose-finding study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC
    Obrocea, Mihail
    Seidl, Brenton
    Joshi, Rohit
    Moore, Melissa
    Vitoc, Vlad
    Yao, Bin
    Gryaznov, Sergei
    CANCER RESEARCH, 2023, 83 (08)
  • [2] A phase 2, multicenter, open-label, dose-optimization study evaluating telomere-targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Updated results
    Jankowski, Tomasz
    Csoszi, Tibor
    Urban, Laszlo
    Nagy, Tunde
    Chilingirova, Nataliya
    Cholakova, Maria
    Joshi, Rohit
    Moore, Melissa M.
    Ramlau, Rodryg
    Soter, Szabolcs
    Kotlarski, Marek
    Koynov, Krassimir Dimitrov
    Mruk, Andrzej
    Seidl, Brenton
    Minchev, Velko
    Muller, Veronika
    Vitoc, Vlad
    Gryaznov, Sergei
    Tudos, Oleg
    Zaporojan, Victor
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results
    Jankowski, T.
    Soter, S.
    Raumlau, R.
    Chilingirova, N.
    Cholakova, M. D.
    Seidl, B.
    Moore, M.
    Joshi, R.
    Vitoc, V.
    Zaporojan, V.
    Gryaznov, S.
    Watkins, P.
    Obrocea, M.
    ANNALS OF ONCOLOGY, 2023, 34
  • [4] An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors
    Di Paola, Eugenio Donato
    Alonso, Silvia
    Giuliani, Rosa
    Calabro, Fabio
    DAlessio, Antonietta
    Regine, Giovanni
    Cerbone, Linda
    Bianchi, Laura
    Mancuso, Andrea
    Sperka, Sabine
    Rozencweig, Marcel
    Sternberg, Cora N.
    FRONTIERS IN ONCOLOGY, 2012, 2
  • [5] A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma
    Carlo-Stella, Carmelo
    Zinzani, Pier Luigi Luigi
    Sureda, Anna
    Araujo, Luis Francisco
    Casasnovas, Olivier
    Carpio, Cecilia
    Yeh, Su-Peng
    Bouabdallah, Krimo
    Cartron, Guillaume
    Kim, Won Seog
    Cordoba, Raul
    Koh, Youngil
    Re, Alessandro
    Alves, Daniela
    Chamuleau, Martine E. D.
    Le Gouill, Steven
    Lopez-Guillermo, Armando
    Moreira, Maria Ilidia
    Van Der Poel, Marjolein W. M.
    Abbadessa, Giovanni
    Meng, Robin
    Ji, Ran
    Lepine, Lucie
    Saleem, Rao
    Ribrag, Vincent
    BLOOD, 2021, 138
  • [6] A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
    Carlo-Stella, Carmelo
    Zinzani, Pier Luigi
    Sureda, Anna
    Araujo, Luis
    Casasnovas, Olivier
    Carpio, Cecilia
    Yeh, Su-Peng
    Bouabdallah, Krimo
    Cartron, Guillaume
    Kim, Won Seog
    Cordoba, Raul
    Koh, Youngil
    Re, Alessandro
    Alves, Daniela
    Chamuleau, Martine
    Le Gouill, Steven
    Lopez-Guillermo, Armando
    Moreira, Ilidia
    van der Poel, Marjolein W. M.
    Abbadessa, Giovanni
    Meng, Robin
    Ji, Ran
    Lepine, Lucie
    Saleem, Rao
    Ribrag, Vincent
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (01) : 108 - 119
  • [7] Preliminary findings from a phase I, open-label, dose-finding study of SNB-101 in patients with advanced solid tumors
    Sang, Y. B.
    Kim, Y.
    Lee, M. A.
    Rha, S. Y.
    Jung, M.
    Lee, C-K.
    Park, Y. H.
    Heo, D.
    Kim, A.
    Kim, J.
    Kim, J-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S474 - S474
  • [8] An open-label phase I dose-finding study of APR-246 in hematological malignancies
    Deneberg, S.
    Cherif, H.
    Lazarevic, V.
    Andersson, P-O
    von Euler, M.
    Juliusson, G.
    Lehmann, S.
    BLOOD CANCER JOURNAL, 2016, 6 : e447 - e447
  • [9] An open-label phase I dose-finding study of APR-246 in hematological malignancies
    S Deneberg
    H Cherif
    V Lazarevic
    P-O Andersson
    M von Euler
    G Juliusson
    S Lehmann
    Blood Cancer Journal, 2016, 6 : e447 - e447
  • [10] Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial
    Gelbenegger, Georg
    Grafeneder, Juergen
    Gager, Gloria M.
    Siller-Matula, Jolanta M.
    Schwameis, Michael
    Jilma, Bernd
    Schoergenhofer, Christian
    THROMBOSIS JOURNAL, 2022, 20 (01)
12345